The presentation of new data on a lead drug candidate at a reputable scientific conference is typically viewed as a positive development. It suggests progress in the drug's development pathway and can lead to increased investor confidence in the company's prospects. This can result in a short-term positive impact on the stock price, although the long-term effects will depend on further clinical results and regulatory approvals.